BML-111 is a lipoxin A4 (LXA4) analog and lipoxin A4 receptor (ALX, formyl peptide receptor 2, FPR2) agonist, inhibits leukotriene B4-induced polymorphonuclear chemotaxis.
BML-111 effectively protected the liver from CCl(4)-induced injury as evidenced by decreased serum aminotransferase (ALT, AST) levels and improved histological damage.
BML-111 markedly upregulated hepatic heme oxygenase-1 (HO-1) expression in CCl(4)-treated mice, which might provide antioxidative activities in the liver.
BML-111 protects podocytes cultured in high-glucose medium against oxidative injury via activating Nrf2 pathway.
BML-111 attenuates ventilator-induced lung injury in rats. suppresses the growth of transplanted H22 tumor in mice through inhibiting tumor-related angiogenesis.
Physicochemical Properties
M.Wt
192.21
Formula
C8H16O5
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
(5S,6R)-Methyl 5,6,7-trihydroxyheptanoate
References
1. Zhang L, et al. Hepatol Res. 2007 Nov;37(11):948-56.
2. Chen Y, et al. Mol Cancer Ther. 2010 Aug;9(8):2164-74.
3. Hao H, et al. Int Immunopharmacol. 2022 Oct;111:109170.
